The study aims to test interactions between drug and placebo-responses in acute migraine treatment and to assess variation in adverse events according to treatment information provided. Using a clinical within-subjects, advanced balanced placebo design, patients with episodic migraine will receive six treatment conditions in a randomized order.
Who can participate
Age range18 Years – 65 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Adults (18-65 years)
✓. ≥ 1-year history of migraine with or without aura according to the International Classification of Headache Disorders (ICHD-3) diagnostic criteria
✓. Known episodic migraine (≥ 1 and \< 15 headache days with features of migraine on at least 2-8 days per month for \> 3 months) with and without aura and diagnosed before age 50
✓. Previous or active use of triptans as acute treatment for migraine
✓. Ability to speak and read Danish
Exclusion criteria
✕. Chronic migraine or history of chronic migraine in the last 12 months
✕. Other concomitant primary headache types except for infrequent tension-type headache
✕. Secondary headache disorders including medication overuse headache
✕. Severe psychiatric, vascular or liver diseases
✕. Opioid or barbiturate use in the month preceding screening
✕. Current use of preventive migraine treatment (i.e., onabotulinum toxin A, and/or Calcitonin gene-related peptide (CGRP) monoclonal antibodies) (however, stable medical treatment with other migraine prophylactic agents is permitted, e.g. antidepressant, calcium channel blockers, beta blockers and antiepileptic drugs, 4 weeks prior to inclusion until the completion of participation in the study)
What they're measuring
1
Headache intensity
Timeframe: Immediately before and 2 hours after each treatment administration
2
Adverse events
Timeframe: 2 hours after each treatment administration